**Additional Table.** Comparison between a control population without almitrine and the whole population receiving almitrine.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Control population****without almitrine** | **Whole population with almitrine** | **p-value** |
|  | **(n= 27)** | **(n= 32)** |  |
| **Variables at admission** |  |  |  |
| Age (years) | 60 [53-67] | 63 [52-69] | 0.86 |
| Male sex, n(%) | 21 (78) | 25 (78) | 1 |
| Body Mass Index (kg/m2) | 29.8 [26.7-34.9] | 33.3 [27.4-36.8] | 0.37 |
| SAPS II | 44 [34-60] | 56 [39-68] | 0.12 |
| SOFA score | 6 [2-8] | 7 [4-10] | 0.18 |
| Comorbidities, n(%) |  |
| Any  | 2 (7) | 7 (22) | 0.20 |
| Hypertension | 14 (52) | 17 (53) | 0.71 |
| Diabetes  | 11 (40) | 10 (30) | 0.70 |
| Respiratory disease  | 7 (26) | 9 (28) | 1 |
| Delay symptoms-admission (days) | 7 [6-9] | 9 [6-12] | 0.06 |
| Invasive mechanical ventilation, n(%) | 27 (100) | 30 (94) | 0.49 |
| Biological data |  |  |  |
|  PaO2/FiO2 ratio | 115 [71-140] | 85 [70-130] | 0.76 |
|  White blood cell count, x109/L | 9 [6.5-11.1] | 9.8 [6.6-14.6] | 0.27 |
|  Lymphocyte count, x109/L | 1 [0.6-1.3] | 0.6 [0.4-0.8] | 0.13 |
|  Platelet count, x109 per L | 226 [168-279] | 249 [163-353] | 0.28 |
|  Fibrinogen, g per L | 7.1 [5.9-8.9] | 7.8 [6.3-8.9] | 0.72 |
|  D-dimer, mcg/mL | 1.9 [1-7.3] | 3.3 [1.6-4.7] | 0.70 |
|  Lactate dehydrogenase, U/L | 471 [409-546] | 470 [366-587] | 0.70 |
|  C-reactive protein, mg/L | 190 [91-309] | 221 [66-276] | 0.62 |
|  Procalcitonin, ng/mL | 0.4 [0.2-3.5] | 0.7 [0.2-1.5] | 0.94 |
| **Treatments during ICU stay** |  |  |  |
| Norepinephrine, n(%) | 23 (85) | 31 (97) | 0.17 |
| Neuromuscular blockers, n(%) | 27 (100) | 30 (94) | 0.49 |
| iNO, n(%) | 9 (33) | 24 (75) | 0.002 |
| Number of prone positioning session, n(%) | 2 [1-3] | 2 [1-4] | 0.83 |
| Renal Replacement Therapy, n(%) | 11 (41) | 16 (50) | 0.60 |
| VV-ECMO, n(%) | 6 (22) | 11 (34) | 0.39 |
| Others treatments |  |  |  |
|  Antiviral drugs | 6 (22) | 5 (16) | 0.74 |
|  Corticosteroids | 16 (59) | 23 (72) | 0.41 |
|  Tocilizumab | 2 (7) | 3 (9) | 1 |
| **Outcomes** |  |  |  |
| Duration of mechanical ventilation (days) | 22 [13-39] | 16 [10-26] | 0.11 |
| ICU length of stay (days) | 25 [15-46] | 17 [12-29] | 0.11 |
| ICU discharge, n(%) | 19 (70) | 15 (47) | 0.11 |
| 28-day mortality rate, n(%) | 8 (30) | 17 (53) | 0.11 |
|  |  |  |  |

Data are expressed as number (%) or median [IQR]. *Comparisons between* control and almitrine populations *were realized with χ2 or Fisher’s exact tests for categorical variables, and Mann-Whitney’s U-test for continuous variables.* *The control population is composed by patients not receiving almitrine with at least one episode of PaO2/FiO2 < 150 mmHg and one prone positioning session during the ICU stay.*

SAPS II, Simplified acute physiology score; SOFA, Sepsis-related organ failure assessment; IQR, interquartile range; iNO, inhaled nitric oxide; PaO2, Arterial partial pressure of oxygen; FiO2, Fraction of inspirited oxygen; VV-ECMO, Venovenous extracorporeal membrane oxygenation; ICU, Intensive care unit